In vivo Efficacy of Posaconazole (POS) against Voriconazole Resistant (VCZ-R) Aspergillus flavus in an Inhalational Neutropenic Murine Model of Invasive Pulmonary Aspergillosis

Natesan, S.K.; L. Cutright, J.

Microbiology Research Journal International: 1-7

2019


ISSN/ISBN: 2456-7043
Accession: 084733275

Download citation:  
Text
  |  
BibTeX
  |  
RIS

Article/Abstract emailed within 1 workday
Payments are secure & encrypted
Powered by Stripe
Powered by PayPal

Abstract
Invasive aspergillosis (IA) is a life-threatening infection in patients with cancer. Recent studies have reported that non-fumigatus Aspergillus spp., including Aspergillus flavus, are emerging as predominant pathogens in various transplant and cancer centers in the USA and around the world. Clinical and environmental isolates of Aspergillus species showing reduced susceptibility to VCZ have been reported. Mortality, despite therapy, remains high, and drug resistance might partly account for treatment failures. In this in vivo study, the virulence of a VCZ-R cyp51A mutant of A. flavus and the efficacy of POS against this mutant were evaluated using a neutropenic inhalational murine model of invasive pulmonary aspergillosis. VCZ-R A. flavus mutant was virulent in vivo, and had similar infectivity as the VCZ-S parent. Posaconazole had superior activity to that of VCZ in reducing fungal burden (p <0.05) and mortality (p <0.05) in this experimental model of VCZ-R A. flavus murine infection. This study demonstrated that POS may be a viable option for certain strains of VCZ-R A. flavus.